Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Il...(intravenous insulin to a range of 80-110...),Health

Date:3/24/2009

intravenous insulin to a range of 80-110 mg/dl. More recent studies in the critical care population were unable to replicate earlier studies, and identified severe hypoglycemia (low blood glucose) as a significant risk of intensive glucose control. The NICE-SUGAR trial was a very large multicenter, multinational study (with 6,104 participants) designed to definitively examine the risks and benefits of intensive glucose control in critical care units.

Results from the NICE-SUGAR study indicate that critically ill patients treated in the intensive glucose control group were 14 percent more likely to die compared to critically ill patients in the conventional glucose control group.

More than 6,100 patients with hyperglycemia in critical care units were randomized to either intensive glucose control (insulin infusion with target blood glucose between 80-108 mg/dl) or to conventional glucose control (insulin infusion begun if blood glucose was over 180 mg/dl, and discontinued if blood glucose dropped below 144 mg/dl). Severe hypoglycemia (blood glucose below 40 mg/dl) occurred in approximately 6.8 percent of intensively treated patients compared to 0.5 percent of conventionally treated patients. The study showed no difference in length of time in the intensive care unit or in the hospital, or in other major outcomes such as time on ventilators or need for dialysis.

About the American Diabetes Association (ADA)

The American Diabetes Association is leading the fight against the deadly consequences of diabetes and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected b
'/>"/>

SOURCE American Association of Clinical Endocrinologists; American Diabetes Association Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. A Joint Statement From Americas Prostate Cancer Advocacy, Education, and Support Organizations
2. Octogenarians: Not Too Old for Joint Replacement
3. Beating Blood Clots after Joint Replacement
4. When to Have That Joint Replacement?
5. Orthopaedic Surgeon Shortage Predicted Due to Soaring Joint Replacement Procedures
6. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
7. Texas Back Institute Leads Way in New Facet Joint Clinical Trial
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
10. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
11. Joint Commission Urges Patients to Speak Up About Pain